Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
"Swire Pacific" H1 2026 Earnings Call - Record Underlying Profit and Record Capital Investment Signal Broad-Based Recovery
Swire Pacific delivered a rare trifecta in the first half of 2026. Recurring underlying profit surged 48% to HKD 7 billion. Capital spending hit record levels. All three core divisions contributed to ...
- Recurring underlying profit hit a record HKD 7 billion, up 48% year over year, fueled by stabilizing consumer sentiment across all divisions.
- Group capital expenditure reached record levels, with management prioritizing execution-phase construction and capacity expansion over new sector bets.
- Property division profit jumped 37%, anchored by the residential trading gain on 6 Deepwater Bay Road and accelerating retail rental income.
- +7 more takeaways
"WPP" 2026 Interim Earnings Call - Stabilizing Revenue Trajectory and Targeting 2027 Growth Amid Structural Overhaul
WPP is in the messy middle of a three-year turnaround, and the first half of 2026 reads like a textbook stabilization phase rather than a victory lap. Like-for-like revenue fell 4.7 percent, but the s...
- H1 like-for-like revenue declined 4.7 percent, but sequential improvement is clear as Q2 narrowed to a 2.8 percent drop. Full-year guidance targets a low-to-mid single-digit decline with a return to organic growth expected in 2027.
- Net new business momentum is strong, topping J.P. Morgan rankings for H1 and the nine months through Q2. Gross client losses will still drag approximately 600 basis points for the full year, but wins are comfortably ahead of 2025 levels.
- H1 headline operating margin expanded to 8.4 percent, up 20 basis points year-over-year, driven by cost discipline and lower severance. Full-year margin guidance remains 12 to 13 percent, with H2 expected to dip up to 200 basis points as reinvestment ramps.
- +7 more takeaways
NuScale Power Q2 2026 Earnings Call - Commercial Deployment Locked Behind Definitive PPA Signings
NuScale’s second quarter paints a clear picture of a company that has spent years building the scaffolding for commercial nuclear and is now waiting for the market to hand over the keys. Revenue contr...
- Liquidity surged to $1.9 billion, up $900 million sequentially, as management shifted from tracking startup burn rates to funding long-term commercial deployment and supply chain commitments.
- Reported revenue fell to $0.1 million in Q2 2026, down from $8.1 million, following the completion of Fluor FEED Phase 2 work for the RoPower project with no immediate replacement activity.
- Management confirmed that TVA and ENTRA1 are in active, daily discussions for a definitive power purchase agreement, describing the utility as progressing toward what could be the largest nuclear deployment in U.S. history.
- +9 more takeaways
TriplePoint Venture Growth BDC Corp Second Quarter 2026 Earnings Call - Accelerating AI Allocation and Exiting Legacy Positions
TriplePoint Venture Growth BDC is methodically shedding the excesses of the 2020 to 2022 venture cycle. The firm exited its largest loan, Prodigy Investments, and tapped a partial Revolut equity sale ...
- TPVG funded $47.8 million in new debt investments during Q2, hitting the top of its $25M to $50M guidance and marking an 80% sequential increase.
- The company exited its largest loan position, Prodigy Investments, for $43.8 million, while partially monetizing a Revolut equity stake for $12.8 million in realized gains.
- PIK income fell to roughly $3 million, representing under 14% of total investment income, as management systematically rotates away from legacy 2020 to 2022 vintages.
- +9 more takeaways
"Array Technologies" Q2 2026 Earnings Call - Record $2.5 Billion Order Book and Raised Profitability Guidance Signal Execution Breakout
Array Technologies delivered a quarter defined by execution and margin expansion, punching well above guidance with $342 million in revenue and 30.8 percent adjusted gross margins. The commercial engi...
- Q2 revenue reached $342 million, surpassing guidance and jumping 53% sequentially, driven by domestic tracker pull-through and strong APA execution.
- Adjusted gross margin expanded to 30.8 percent, with profitability flow-through pushing adjusted EBITDA to $63 million and adjusted EPS to $0.24.
- The order book hit a record $2.5 billion for the third consecutive quarter, supported by a 1.5x trailing book-to-bill ratio and over $500 million in new bookings.
- +9 more takeaways
"Joby Aviation" Q2 2026 Earnings Call - Revenue Guidance Raised as Blade Momentum Fuels Commercialization Push
Joby Aviation is no longer just selling a vision of electric flight. It is building the operating system around it. The second quarter delivered a clear signal that the commercialization clock is tick...
- Joby raised full-year revenue guidance to $115 million to $125 million, driven by a 32 percent year-over-year revenue jump in the first half of 2026 from its Blade division.
- Blade posted a record second quarter with seats sold up 50 percent year-over-year, shifting the primary growth constraint from passenger demand to aircraft availability.
- The company confirmed it will launch its first eIPP flights in Texas next month, following a staged rollout that begins with pilots, moves to non-paying passengers, and targets paying passengers within 2026.
- +9 more takeaways
"Dutch Bros" Q2 2026 Earnings Call - Raised Full-Year Guidance as Comp Sales and Pipeline Momentum Accelerate
Dutch Bros delivered another quarter of compounding momentum, with Q2 revenue jumping 32 percent to $551 million and company-operated same-shop sales climbing 8.3 percent. The acceleration is not a st...
- Revenue and comp growth accelerate: Q2 revenue hit $551M (+32% YoY), with company comp sales up 8.3% and system-wide up 5.8%. Eight straight quarters of transaction growth prove the playbook works.
- Full-year guidance raised: Management lifted system same-shop sales guidance to 5%-6%, trending toward the midpoint. Revenue guidance now sits at $2.1B to $2.13B (+28-30% YoY).
- Food program rollout ahead of schedule: The new hot food platform hit ~750 company shops in Q2. Attach rates are climbing, directly attacking the morning occasion and widening the comp gap between company and franchise stores.
- +7 more takeaways
Senestech Q2 FY2026 Earnings Call - Record Revenue and Margin Expansion Driven by Direct E-commerce Control
Senestech’s second quarter marks a decisive pivot from research-heavy experimentation to a revenue-driven operating model. Bringing Amazon and direct-to-consumer channels in-house delivered a 56% sequ...
- Q2 revenue hit a record $770,000, up 56% sequentially, as the company completed its transition to direct e-commerce management.
- Amazon sales surged 473% quarter-over-quarter to $349,000, validating the shift from external management to in-house channel control.
- Subscription revenue reached $104,000, up 89% sequentially, confirming that Evolve is transitioning from a one-time purchase to a recurring rodent management program.
- +9 more takeaways
Paysign Q2 2026 Earnings Call - Revenue surges 48% as Patient Affordability scales and Plasma normalizes, driving raised full-year outlook
Paysign’s second quarter was less about beating guidance and more about proving a dual-engine model is actually working. Revenue jumped 48% to $28.3 million, with patient affordability acting as the p...
- Total revenue surged 48% year-over-year to $28.3 million, marking the second consecutive quarter of exceeding internal guidance.
- Patient affordability revenue jumped 89% to $14.6 million, driven by a 54% increase in claim volume and 13 new program launches in the quarter.
- Gross margin expanded 170 basis points to 63.3%, reflecting a favorable mix shift toward higher-margin pharma services and strong operating leverage.
- +7 more takeaways
"Coherus Oncology Inc." Q2 2026 Earnings Call - LOQTORZI Sales Rebound to $13.6 Million as Tagmokitug Data Catalyst Looms in October
Coherus is proving that biotech survival still hinges on commercial execution and surgical cost control. LOQTORZI sales jumped 15 percent to $13.6 million in the second quarter, driven by a rebound in...
- LOQTORZI Q2 net sales reached $13.6 million, marking a 15 percent quarter-over-quarter rebound as new patient starts hit a post-launch high.
- Management projects full-year 2026 revenue between $57 million and $62 million, maintaining a path to $30 million per quarter by 2027.
- The company is actively correcting physician misdosing habits, particularly around Q2W versus Q3W administration and early discontinuations, to unlock duration upside.
- +7 more takeaways